NASDAQ · NAUT
Nautilus Biotechnology, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for NAUT has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Mar 2027 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Jun 2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Sep 2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · RTTNews · MarketBeat · Fintel- The Motley Fool · Oct 27, 1:29 PM EDTNautilus (NAUT) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Oct 27, 12:14 PM EDTNautilus Biotechnology Reports Q3 Results; Expects Up To $6M From ARPA-H-Funded Consortium(RTTNews) – Nautilus Biotechnology, Inc. (NAUT) reported third quarter 2026 financial results and announced progress in its proteomics platform development, including participation in a four-year research consortium funded by the Advanced Research Projects Agency for Health (ARPA
- MarketBeat · Oct 27, 11:05 AM EDTNautilus Biotechnology Q3 Earnings Call HighlightsNautilus Biotechnology (NASDAQ:NAUT) reported third-quarter revenue of $200,000 as it continued its transition toward commercialization of its Voyager proteomics platform, with management reaffirming plans to begin taking platform pre-orders in early 2027 and start instrument shi
- Fintel · Oct 27, 6:42 AM EDTNautilus Biotechnology Reports Third Quarter 2026 Financial ResultsNautilus Biotechnology, Inc. reported its financial results for the third quarter ended September 30, 2026. Revenue was $0.2 million for the third quarter of 2026, primarily driven by grant revenue from the Company’s activities related to the grant awarded from The Michael
- Fintel · Sep 29, 8:51 PM EDTRoth Capital Initiates Coverage of Nautilus Biotechnology with BuyFintel reports that on September 29, 2026, Roth Capital initiated coverage of Nautilus Biotechnology (NASDAQCM:NAUT) with a Buy recommendation.On the day of the coverage initiation, September 29, 2026, the latest close for the stock was $1.36. This follows a pre-action close of $
- Fintel · Sep 9, 10:19 PM EDTLeerink Partners Initiates Coverage of Nautilus Biotechnology with OutperformFintel reports that on September 9, 2026, Leerink Partners initiated coverage of Nautilus Biotechnology (NASDAQCM:NAUT) with a Outperform recommendation.Prior to this rating action, the stock closed at $0.93 on September 8, 2026. This represents a one-week price change of +0.15%
- RTTNews · Sep 4, 10:05 AM EDTNautilus Biotechnology Reveals Tau Proteoform Insights In Nature Methods Publication(RTTNews) – Nautilus Biotechnology, Inc. (NAUT), a development-stage life sciences company focused on single-molecule proteomics, on Friday announced a peer-reviewed publication in Nature Methods demonstrating its Iterative Mapping technology for large-scale analysis of tau prote
- RTTNews · Jul 29, 2:07 AM EDTNautilus Reports Q2 Results And Reaffirms 2027 Voyager Launch; Stock Falls 27%(RTTNews) – Nautilus Biotechnology (NAUT) on Tuesday reported second-quarter financial results, turning a narrower net loss than the previous year.
- MarketBeat · Jul 28, 10:04 AM EDTNautilus Biotechnology Q2 Earnings Call HighlightsNautilus Biotechnology (NASDAQ:NAUT) said it is shifting a significant share of its research and development resources toward proteoform applications, citing customer interest and a delay in its Broadscale broad-proteome program. Chief Executive Officer Sujal Patel said the comp
- The Motley Fool · Jun 2, 9:56 AM EDTNautilus (NAUT) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Apr 28, 9:48 AM EDTNautilus Reports Q1 Results, Advances Early Access And Platform Development; Stock Up(RTTNews) – Nautilus Biotechnology, Inc. (NAUT), a company developing a single-molecule proteome analysis platform, reported its financial results for the first quarter ended March 31, 2026, highlighting progress toward commercialization and continued platform development.
- Fintel · Mar 27, 5:37 AM EDTNautilus Biotechnology (NAUT) Price Target Increased by 60.00% to 4.08The average one-year price target for Nautilus Biotechnology (NasdaqCM:NAUT) has been revised to $4.08 / share. This is an increase of 60.00% from the prior estimate of $2.55 dated February 21, 2026. The price target is an average of many targets provided by a
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Nautilus Biotechnology, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.